Examkin

Question

Difficulty: MediumSleep-Wake Disorders

A 26-year-old woman is evaluated in the sleep clinic for a 1-year history of irresistible daytime sleep attacks. She reports frequently falling asleep during meetings and while driving. Additionally, she experiences vivid, frightening hallucinations just as she is falling asleep, and transient periods of bilateral leg weakness triggered by sudden laughter. She takes no medications and her physical examination is unremarkable. Arrange the following steps in the most appropriate chronological sequence for the diagnostic evaluation and step-wise pharmacological management of this patient.

  1. 1Review a two-week sleep diary to assess baseline sleep-wake patterns and rule out chronic sleep deprivation.
  2. 2Conduct an overnight polysomnography to evaluate for other sleep disorders and document adequate prior sleep.
  3. 3Perform a Multiple Sleep Latency Test (MSLT) to identify a shortened mean sleep latency and sleep-onset REM periods.
  4. 4Initiate daytime treatment with a wake-promoting agent such as modafinil for excessive daytime sleepiness.
  5. 5Add a rapid eye movement (REM) sleep-suppressing medication such as venlafaxine to manage cataplexy.

Answer

The correct sequence is: 1) Review a two-week sleep diary, 2) Conduct an overnight polysomnography, 3) Perform a Multiple Sleep Latency Test (MSLT), 4) Initiate modafinil, 5) Add venlafaxine.
The evaluation of suspected narcolepsy type 1 begins with a sleep diary to verify that excessive daytime sleepiness is not simply due to chronic sleep deprivation. Next, an overnight polysomnography (PSG) is strictly required to rule out other sleep disorders (e.g., sleep apnea) and to document at least 6 hours of sleep. The following day, a Multiple Sleep Latency Test (MSLT) is performed to objectively confirm narcolepsy by demonstrating a mean sleep latency of less than 8 minutes and at least two sleep-onset REM periods. Therapeutically, the stepwise approach first addresses excessive daytime sleepiness with a wake-promoting agent like modafinil. Once daytime wakefulness is improved, targeted therapy for cataplexy (emotionally triggered muscle weakness) is added using an REM-suppressing medication such as an SNRI (e.g., venlafaxine).

Step-by-Step Solution

1
Evaluate the initial diagnostic requirement.
A sleep diary is reviewed.
To establish baseline sleep-wake patterns and rule out chronic sleep deprivation or circadian rhythm disorders prior to formal objective testing.
2
Determine the first objective diagnostic study.
Overnight polysomnography is conducted.
To rule out co-occurring sleep disorders such as obstructive sleep apnea and to confirm the patient has slept enough (at least 6 hours) to validate subsequent daytime testing.
3
Determine the confirmatory diagnostic test.
Multiple Sleep Latency Test (MSLT) is performed.
Conducted the day after polysomnography to detect a shortened sleep latency (under 8 minutes) and at least two sleep-onset REM periods (SOREMPs), which confirms narcolepsy.
4
Establish the initial pharmacological intervention.
Modafinil is prescribed.
Wake-promoting agents are the first-line treatment for managing excessive daytime sleepiness, which is generally the most pervasive and debilitating symptom.
5
Address the patient's cataplexy.
Venlafaxine is added to the regimen.
An SNRI strongly suppresses REM sleep and is highly effective at preventing the emotionally triggered sudden loss of muscle tone (cataplexy) seen in narcolepsy type 1.

Key Concept

Diagnosis and Stepwise Management of Narcolepsy Type 1
Rate this question

Topics

Sleep-Wake Disorders

More questions from this topic